Dianthus Therapeutics, Inc. /DE/ (DNTH) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 175.60M USD | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 34.27M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -217.84M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $175.60M | (m) | $34.27M | $-217.84M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $153.16M | (m) | $28.08M | $-191.29M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $145.64M | $2.04M | $22.79M | $-177.93M | (m) | 7153.14% | 1119.50% | (m) | (m) |
| 2025-09-30 | $116.95M | $3.08M | $20.73M | $-140.31M | (m) | 3799.58% | 673.59% | (m) | (m) |
| 2025-06-30 | $105.21M | $4.85M | $18.78M | $-129.92M | (m) | 2167.51% | 386.88% | (m) | (m) |
| 2025-03-31 | $97.03M | $6.52M | $16.17M | $-117.20M | (m) | 1487.28% | 247.92% | (m) | (m) |
| 2024-12-31 | $83.11M | $6.24M | $12.89M | $-101.86M | (m) | 1332.88% | 206.80% | (m) | (m) |
| 2024-09-30 | $65.47M | (m) | $9.70M | $-82.90M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $47.89M | (m) | $7.04M | $-68.76M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $40.07M | (m) | $4.40M | $-58.34M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $32.84M | (m) | $2.90M | $-48.17M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $59.65M | (m) | $8.19M | $-97.11M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $35.13M | (m) | $4.19M | $-78.49M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $46.59M | (m) | $5.62M | $-89.20M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $55.14M | (m) | $7.02M | $-80.90M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $52.47M | (m) | $7.44M | $-79.31M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $52.06M | (m) | $9.73M | $-80.30M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $51.59M | (m) | $10.02M | $-79.83M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $46.77M | (m) | $10.31M | $-74.69M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $45.91M | (m) | $10.46M | $-73.62M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $46.90M | (m) | $9.02M | $-73.75M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $48.38M | (m) | $9.39M | $-76.16M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $50.62M | (m) | $9.94M | $-78.70M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $57.07M | $0.00 | $9.67M | $-84.27M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $61.81M | $0.00 | $10.07M | $-88.54M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $62.63M | $0.00 | $10.16M | $-87.86M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $59.21M | $0.00 | $10.00M | $-82.97M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $52.88M | $0.00 | $10.49M | $-76.26M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $47.78M | $0.00 | $11.40M | $-70.32M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $44.03M | $0.00 | $11.86M | $-65.01M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $41.34M | $0.00 | $10.70M | $-59.96M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $0.00 | (m) | $-42.22M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $27.90M | $0.00 | $2.26M | $-35.73M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $5.78M | $0.00 | $662.00K | $-9.27M | $163.00K | (m) | (m) | -56.86× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |